On February 2, 2026, the Taiwan Food and Drug Administration (TFDA), under the Ministry of Health and Welfare, announced a revision to the annex of the Documentation Required for Case-by-Case Review of Applications for the Use of Human Cell-Derived Exosomes in Cosmetics. The revised annex takes effect immediately upon the date of announcement.
Since the concept of New Approach Methodologies (NAMs) was introduced, various methods including in vitro approaches, Threshold of Toxicological Concern (TTC), and computational models have gained favor among toxicological assessment experts. With the increasing capabilities of computational models, key toxicological endpoints such as acute toxicity, skin/eye irritation, sensitization, chronic toxicity, genotoxicity, carcinogenicity, reproductive and developmental toxicity, and toxicokinetics can now be predicted using QSAR models.
Contact Us
